# KELIM Developer Engagement Plan
## D6: Colomban Group Outreach & Collaboration

**Date:** December 26, 2024  
**Target:** Colomban Group (KELIM developers)  
**Contact:** biomarkers.kinetics@univ-lyon1.fr  
**Institution:** Centre LÃ©on BÃ©rard, Lyon, France

---

## KEY RESEARCHERS

### Primary Contact (Likely)
**Dr. BenoÃ®t You**
- Institution: Centre LÃ©on BÃ©rard, Lyon, France
- Research: KELIM methodology, CA-125 kinetics, ovarian cancer
- Publications: Multiple KELIM validation papers (ICON-7, GOG-0218, VELIA, PAOLA-1)

**Research Needed:**
- [ ] Confirm exact name and title
- [ ] Find direct email (if different from group email)
- [ ] ResearchGate / LinkedIn profile
- [ ] Recent publications (2020-2024)

### Co-Developers
**Dr. [NAME]** - Co-developer, statistician, biomarker researcher

**Research Needed:**
- [ ] Identify co-developers from KELIM papers
- [ ] Find contact information
- [ ] ResearchGate / LinkedIn profiles

---

## EMAIL TEMPLATE

### Subject: Extending KELIM with MAPK Genetics: Multi-Modal Validation Collaboration

**Body:**

Dear Dr. You and Colomban Group,

I'm reaching out because your work on KELIM (CA-125 ELIMination rate constant K) has been foundational to our understanding of early platinum resistance detection in ovarian cancer. Your validation across 12+ trials (n>12,000 patients) proves that CA-125 kinetics workâ€”yet KELIM remains unused in clinical practice.

**We're extending your work with a critical addition: MAPK genetics.**

**What We've Built:**
- Validated MAPK/NF1 mutations as baseline resistance signal (TCGA-OV, n=469, RR=1.97, p=0.05)
- Hypothesis: **MAPK genetics + KELIM kinetics = multi-modal advantage** (AUROC target: 0.65-0.75 vs. 0.60 single modality)
- Earlier detection: Week 6-9 (vs. KELIM's traditional week 12-15)
- Full validation harness: Deterministic scripts, pinned cohorts, report.json receipts

**What We Need:**
1. **Batch KELIM Calculator Access** (Option A)
   - Request: Access to your KELIM calculation tool/API for batch processing
   - Use case: Calculate KELIM scores for TCGA-OV patients (if serial CA-125 available) or external collaborator cohorts
   - Offer: Co-authorship on multi-modal validation paper

2. **Validation Dataset** (Option B)
   - Request: De-identified validation dataset with:
     - Serial CA-125 measurements (â‰¥3 timepoints)
     - Platinum-free interval (PFI) labels
     - Resistance outcomes
     - Patient cohort: nâ‰¥50 (ideally nâ‰¥100)
   - Use case: Validate multi-modal (MAPK + KELIM) hypothesis
   - Offer: Co-authorship on multi-modal validation paper

3. **Collaboration & Guidance** (Option C)
   - Request: Expert guidance on KELIM calculation methodology
   - Use case: Ensure our KELIM implementation matches your validated approach
   - Offer: Co-authorship on multi-modal validation paper

**What We Offer:**
- **Co-authorship guaranteed** (even if multi-modal failsâ€”negative results published)
- Full transparency: All code, methods, receipts open-source
- Payer-aligned approach: Addresses reimbursement barriers that prevented KELIM adoption
- Adversarial framing: "Resurrecting buried science" narrative (positions KELIM as validated but suppressed)

**Why This Matters:**
KELIM was validated but never adopted. Economic forces ($10B+ revenue threat to pharma/diagnostics) buried it. We're resurrecting it + making it better (multi-modal, earlier, productized). Your collaboration would be critical to proving this works.

**Our Validation Protocol:**
- Endpoint: Platinum resistance (PFI < 6 months)
- Input: Mutations (MAPK status) + serial CA-125 (KELIM)
- Output: Multi-modal risk score + mechanisms + actions
- Validation: External cohorts (nâ‰¥50 per site)
- Timeline: 4-6 weeks per site

**Next Steps:**
- If interested, I can send our full validation protocol (IRB-ready)
- We can schedule a brief call to discuss collaboration terms
- Timeline: Ready to start immediately

**Questions:**
1. Would you be open to providing batch KELIM calculator access or validation dataset?
2. Are there specific collaboration terms you'd like to discuss?
3. Would you be interested in co-authoring the multi-modal validation paper?

Thank you for your groundbreaking work on KELIM. Let's get it into clinical practice.

Best regards,  
Fahad Kiani  
CrisPRO.ai  
ðŸ“§ Fahad@CrisPRO.ai  
ðŸ“± [PHONE NUMBER]

---

## RESEARCHGATE / LINKEDIN OUTREACH

### If Email Doesn't Work

**ResearchGate:**
- Search: "BenoÃ®t You" + "KELIM" + "ovarian cancer"
- Find profile
- Send direct message (similar to email template)

**LinkedIn:**
- Search: "BenoÃ®t You" + "Centre LÃ©on BÃ©rard"
- Find profile
- Send connection request + message (similar to email template)

**Alternative Contact Methods:**
- Centre LÃ©on BÃ©rard website: Department contact
- University of Lyon website: Faculty directory
- Recent publications: Corresponding author email

---

## COLLABORATION TERMS (To Discuss)

### What We're Proposing

1. **Data Sharing:**
   - De-identified patient data only
   - Secure transfer (encrypted, HIPAA-compliant if US data)
   - Data use agreement (academic research only)

2. **Co-Authorship:**
   - Guaranteed co-authorship on multi-modal validation paper
   - Even if multi-modal fails (negative results published)
   - Authorship order: Negotiable (likely: Fahad first, Colomban group contributors)

3. **Intellectual Property:**
   - KELIM methodology: Remains with Colomban group (their IP)
   - Multi-modal extension: Joint IP (to be discussed)
   - Open-source: All code, methods, receipts open-source (academic transparency)

4. **Timeline:**
   - Immediate: Ready to start
   - Data acquisition: 2-4 weeks (if external cohorts)
   - Analysis: 2-4 weeks
   - Paper writing: 4-6 weeks
   - Total: 8-14 weeks to publication-ready

5. **Funding:**
   - Our side: Self-funded (no external grants)
   - Their side: No funding required (data sharing only)
   - Publication costs: We cover (open-access if desired)

---

## SUCCESS CRITERIA

**By Tuesday:**
- âœ… Email sent to Colomban group
- âœ… ResearchGate / LinkedIn message sent (if email doesn't work)
- ðŸŽ¯ Target: Response within 48 hours
- ðŸŽ¯ Success: Collaboration terms discussed
- ðŸŽ¯ Stretch: Batch calculator access OR validation dataset committed

---

## FOLLOW-UP PLAN

### If No Response (48 hours)
- [ ] Send follow-up email (gentle reminder)
- [ ] Try ResearchGate / LinkedIn message
- [ ] Try alternative contact (Centre LÃ©on BÃ©rard department)

### If Response (Positive)
- [ ] Schedule call to discuss collaboration terms
- [ ] Send validation protocol
- [ ] Negotiate data sharing agreement
- [ ] Set timeline for collaboration

### If Response (Negative)
- [ ] Thank them for consideration
- [ ] Ask if they know other researchers who might be interested
- [ ] Keep door open for future collaboration

---

## NOTES

**Why This Matters:**
- Colomban group = original KELIM developers
- They have validation datasets and calculation tools
- Their collaboration = credibility + access to data
- Co-authorship = academic legitimacy

**Positioning:**
- We're extending their work (not replacing it)
- We're addressing barriers that prevented KELIM adoption
- We're making KELIM better (multi-modal, earlier, productized)
- We're resurrecting buried science (adversarial framing)

**Risk Mitigation:**
- If they say no: We proceed with external cohorts (D5)
- If they say yes: We get expert guidance + potential data access
- Either way: We move forward with validation

---

**END OF PLAN**

**Next Steps:**
1. Research exact contact information (name, email, ResearchGate/LinkedIn)
2. Send email (primary method)
3. Send ResearchGate/LinkedIn message (backup)
4. Follow up if no response (48 hours)































